Neurocrine Biosciences Supports
TD Awareness Week

Neurocrine Biosciences is committed to bringing awareness to TD every day, but especially during Tardive Dyskinesia Awareness Week (TDAW). Every year, we recognize the first full week in May as another opportunity to raise awareness and education around TD.

We aren’t the only ones who support this mission. As of this year, all 50 states, Washington, D.C., and various mental health advocacy organizations, have declared the first week in May as TD Awareness Week.

 

USA Map

The Impact of TD

TD is estimated to affect approximately 600,000 people in the U.S. Although it can look or feel different from day to day, TD is a chronic condition and symptoms may be persistent. In a survey, patients with diagnosed or suspected TD reported the condition moderately or extremely affected them in the following areas*:
• 46% Ability to work
• 53% Ability to sleep
• 35% Ability to eat and drink

TD can impact patients socially, emotionally, and physically. Symptoms can make them feel embarrassed or judged by others and, in some cases, lead them to withdraw from society and isolate themselves from the outside world.

For those seeking help with TD, a potential treatment is available.

*The survey evaluated 1,000 patients on medications such as antipsychotics.
Base: Patient ATU 2021: Target patients (n=350). Responses based on survey question: Since first experiencing involuntary movements, how has your ability to perform the following daily activities been affected, if at all? Rating scale: 1 to 5 when 1 means “not affected at all,” and 5 means “extremely negatively affected.”

FAQ

What is tardive dyskinesia?
Tardive dyskinesia (TD) is an involuntary movement disorder that is associated with taking certain mental health medications (antipsychotics). TD is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts.

Who is at risk for developing TD?
People living with a mental illness, such as bipolar disorder, depression, schizophrenia, or schizoaffective disorder, who take antipsychotics for a prolonged time may develop TD. Other factors may also play a role in an individual’s risk for TD.
• Having a mood disorder, such as depression or bipolar disorder
• Being 50 years of age or older
• Substance use disorder
• Being post-menopausal

Why is it important to prioritize TD awareness?
Despite the number of people impacted by the condition, many people are still unfamiliar with TD. However, for patients living with TD, their families, and their caregivers, it is important to know that they are not alone. While approximately 25% of patients with TD have been diagnosed, approximately 75% of those potentially living with TD have not yet been diagnosed. Increasing awareness will help more patients get the diagnosis and help that they need.

When is TD Awareness Week?
Tardive Dyskinesia Awareness Week (TDAW) is the first full week of May. May is also Mental Health Awareness Month, which brings attention to the 1 in 5 U.S. adults that live with a mental illness. As we work to increase awareness and support for those impacted by mental health conditions, it is important to remember that those living with a mental illness and taking antipsychotics for a prolonged time may develop or already have TD.

How many states have recognized TD Awareness Week?
50 states and Washington, D.C., have declared the first week in May as TD Awareness Week.

Where can I learn more about TD?
To learn more about TD, download resources, or hear real stories from people with TD, visit TalkAboutTD.com. Healthcare professionals can also visit MIND-TD.com to learn more about TD.

Where can I learn about a potential treatment for TD?
For people looking for help with TD symptoms, a potential treatment is available.

 

Corporate Social Responsibility

Our ESG programs are aligned to our purpose, which we fulfill through effective management of critical environmental, social, and governance principles that are fundamental to our business.

Learn More
Pipeline

At Neurocrine Biosciences, we have a robust pipeline of investigational therapies with the potential to address unmet clinical needs of patients living with neurological, endocrine and psychiatric disorders.

Learn More